Disease severity affects the long-term visual outcome of Peter's anomaly.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI
According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”
Higher Molar Dose and Its Translation into Clinical Practice
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop
The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension
Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)
The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests